ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Rheumatoid Factor"

  • Abstract Number: 0458 • ACR Convergence 2024

    Long-Term Outcomes in Seronegative Rheumatoid Arthritis

    Bradly Kimbrough1, Cynthia Crowson2, Sara Achenbach3 and Elena Myasoedova2, 1Mayo Clinic Rochester, Rochester, MN, 2Mayo Clinic, Rochester, MN, 3Mayo Clinic, Rochester, Rochester, MN

    Background/Purpose: Seronegative rheumatoid arthritis (RA) is a heterogenous disease distinct from seropositive RA regarding genetic risk factors, pathobiology, and prognosis. Notably, recent studies have shown…
  • Abstract Number: 2302 • ACR Convergence 2024

    A Specific Molecular Profiling of Secreted Rheumatoid Factors in Sjögren’ S Disease Patients with Lymphoma

    Jing Jing Wang1, Bridie Armour1, Alexander Troelnikov1, Tim Chataway1, Veronique LE GUERN2, Eric Hachulla3, Alain SARAUX4, Claire Larroche5, Jacques-Eric Gottenberg6, Xavier Mariette7 and Gaetane Nocturne7, 1Flinders University, Adeleide, Australia, 2Cochin hospital, Paris, France, 3University of Lille, LILLE, France, 4CHU Brest, Brest, France, 5Avicenne University Hospital, Avicenne, France, 6Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, 7Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France

    Background/Purpose: Sjogren’s disease (SjD) is characterized by an increased risk of lymphoma (x 10-15 compared to the general population). We and others have previously demonstrated…
  • Abstract Number: 0475 • ACR Convergence 2024

    Rheumatoid Arthritis – Progressive Interstitial Lung Disease with Abatacept: Data from a Large National Multicenter Cohort

    Ana Serrano-Combarro1, Belén Atienza-Mateo2, Libe Ibarrola Paino3, Ivette Casafont-Sole4, Jesús Loarce5, Juan María Blanco Madrigal6, Santos Castañeda7, Rafaela Ortega-Castro8, Natalia Mena Vázquez9, Nuria Vegas Revenga10, Lucia Cristina Dominguez Casas11, Cilia Peralta Ginés12, Carolina Diez Morrondo13, Lorena Pérez Albadalejo14, Rubén López Sánchez15, MARIA GUADALUPE MANZANO CANABAL16, Anahy Maria Brandy-Garcia17, Patricia Lopez Viejo18, Gema Bonilla19, Olga Maíz Alonso20, Carmen Carrasco-Cubero21, Marta Garijo Bufort22, Mireia Moreno Martinez-Losa23, Ana Urruticoechea-Arana24, Sergi Ordoñez25, Carmen González Montagut26, Andrea García-Valle27, Juan Ramón De Dios28, Patricia Carreira29, Tomás Vázquez Rodríguez30, Delia Fernández-Lozano31, Ignacio Brana Abascal32, Rafael Benito Melero-Gonzalez33, Emilio Giner34, Virginia Ruiz Esquide35, Clara Ventin Rodriguez36, Marina Rodriguez37, Pablo Andújar-Brazal38, Julia Fernandez Melon39, Lilian M. López-Núñez40, JOSE RAMON LAMUA RIAZUELO41, Carlos Fernández Díaz42, Javier Loricera43 and Ricardo Blanco-Alonso44, 1Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, 2Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, 3Rheumatology Division, Bisadoa Hospital, Bidasoa, Spain, 4Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 5Ramón y Cajal University Hospital, Madrid, Madrid, Spain, 6Basurto University Hospital, Bilbao, Spain, 7Hospital Universitario de la Princesa, Madrid, Spain, 8Hospital Reina Sofía, Cordoba, Andalucia, Spain, 9IBIMA, Málaga, Andalucia, Spain, 10Hospital Galdakao- Usansolo, Galdakao, Spain, 11Hospital Universtario San Agustin, Oviedo, Spain, 12Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, 13Hospital de Leon, León, Spain, 14Hospital Universitario de Jaén, Jaén, Spain, 15Hospital Universitario de Gran Canaria Dr. Negrín, Gran Canaria, Spain, 16CAZA, Salamanca, Spain, 17Hospital Germans Trias i Pujol, Badalona, Spain, 18Hospital Severo Ochoa, Madrid, Madrid, Spain, 19H. Universitario La Paz, Madrid, Spain, 203Hospital Universitario de Donosti, San Sebastian, Spain, San Sebastian, Pais Vasco, Spain, 21Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, 22Hospital de Sagunto, Valencia, Spain, 23Parc Tauli Hospital Universitari, I3PT(UAB), Barcelona, Spain, 24Hospital Son Espases, Palma de Mallorca, Islas Baleares, Spain, 25Hospital Universitario Arnau de Vilanova de Lleida, Lleida, Spain, 26Hospital Universitario de Valladolid, Valladolid, Spain, 27Hospital General Río Carrión, Palencia, Spain, 28Osakidetza, Vitoria, Spain, 29Hospital Universitario 12 de Octubre, Madrid, Madrid, Spain, 30Complejo Hospitalario Universitario de Ferrol, Ferrol, Spain, 31Hospital Clínico Universitario de Valencia, Valencia, Spain, 32Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain, 33CHU Ourense, O Carballino, Spain, 34Hospital Royo Villanova, Teruel, Spain, 35Hospital Clinic Barcelona, Barcelona, Spain, 36Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, 37Hospital Clínico Universitario de Santiago, La Coruna, Spain, 38Hospital Universitario Doctor Peset, Valencia, Spain, 39Hospital Son Espases, Palma, Spain, 40Hospital Universitari Son Llàtzer, Palma, Spain, 41Hospital Universitario del Henares, Madrid, Spain, 42Hospital Universitario Santa Lucía, Cartagena, Spain, 43Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 44Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

    Background/Purpose: Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Abatacept (ABA) has demonstrated effectiveness in the treatment of RA-ILD, regardless…
  • Abstract Number: 2671 • ACR Convergence 2024

    Subcutaneous Abatacept vs Adalimumab Head-to-Head Comparison in Adults with Early, Dual Seropositive Rheumatoid Arthritis, Positive for the Shared Epitope HLA Class II Risk Alleles, and an Inadequate Response to Methotrexate: Results from a Phase 3 Trial

    Michael Weinblatt1, Paul Emery2, Vivian Bykerk3, Andrew Cope4, Gerd Burmester5, Yoshiya Tanaka6, Gustavo Citera7, Peter Nash8, Quentin Dornic9, Sheila Kelly10 and Michael Maldonado9, 1Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, 2University of Leeds, Leeds, United Kingdom, 3Hospital For Special Surgery, New York, NY, 4King's College London, London, United Kingdom, 5Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 6Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, 7Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 8Griffith University, Brisbane, Australia, 9Bristol Myers Squibb, Princeton, NJ, 10Bristol Myers Squibb, Doylestown, PA

    Background/Purpose: For patients (pts) early in their RA disease course, with a clinical profile characterized by inadequate response to MTX (MTX-IR), high titers of ACPA…
  • Abstract Number: 0488 • ACR Convergence 2024

    Association of Anti-CarP Levels with Clinical Activity and Serological Profile in Rheumatoid Arthritis

    Pablo Martínez Calabuig1, Elena Grau García2, Samuel Leal Rodriguez2, Ernesto Tovar Sugrañes3, José Ivorra-Cortés4, Carmen Riesco Barcena3, Anderson Huaylla Quispe3, Laura Mas Sánchez5, Pablo Muñoz Martínez6, Daniel Ramos Castro3, Alba Torrat noves7, Iago Alcantara Alvarez8, Belén Villanueva Mañés8, Miguel Simeo Vinaixa8, Andrés Pérez Hurtado3 and Jose A Román-Ivorra9, 1HOSPITAL GENERAL UNIVERSITARIO VALENCIA SPAIN, Ontinyent, Comunidad Valenciana, Spain, 2HUP La Fe, Valencia, Spain, 3Rheumatology Department. HUP La Fe, Valencia, Spain, 4Hospital Universitario La Fe, PALMA DE MALLORCA, Spain, 5Resident at Hospital Universitari i Politecnic La Fe, Valéncia, Spain, 6Hospital Universitario y Politècnico La Fe, Sagunto, Spain, 7Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Comunidad Valenciana, Spain, 8Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, 9Hospital Universitari i Politècnic la Fe, Valencia, Comunidad Valenciana, Spain

    Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease where the presence of rheumatoid factor (RF) and anti-citrullinated peptide antibodies (antiCCP) has been associated to…
  • Abstract Number: 0498 • ACR Convergence 2024

    ACPA Subtypes, RF Isotypes, and the Risk of Rheumatoid Arthritis-Associated Interstitial Lung Disease

    Jacob Welch1, Yangyuna Yang1, Joshua Baker2, Katherine Wysham3, Dana Ascherman4, Paul Monach5, Gail Kerr6, Andreas Reimold7, grant Cannon8, Gary Kunkel9, William Robinson10, Michael Duryee1, Geoffrey Thiele1, Ted Mikuls1 and Bryant England1, 1University of Nebraska Medical Center, Omaha, NE, 2University of Pennsylvania, Philadelphia, PA, 3VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, 4Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, 5VA Boston Healthcare System, Boston, MA, 6Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 7Dallas VA Medical Center, Dallas, TX, 8University of Utah and Salt Lake City VA, Salt Lake City, UT, 9University of Utah and George E Wahlen VAMC, Salt Lake City, UT, 10Stanford University, Palo Alto, CA

    Background/Purpose: Interstitial lung disease (ILD) is among the most significant extra-articular manifestations of rheumatoid arthritis (RA), clinically affecting 8-15% of RA patients, and accounting for…
  • Abstract Number: 1296 • ACR Convergence 2023

    Decline in Incidence of Extraarticular Manifestations of Rheumatoid Arthritis: A Population-Based Cohort Study

    Bradly Kimbrough1, Cynthia Crowson1, John Davis1, Eric Matteson2 and Elena Myasoedova1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic College of Medicine and Science, Rochester, MN, USA, Rochester, MN

    Background/Purpose: Extraarticular manifestations of rheumatoid arthritis (ExRA) are associated with increased disease burden and mortality. They are also common, affecting about half of patients with…
  • Abstract Number: 1308 • ACR Convergence 2023

    Certolizumab Pegol Shows Longer Retention Rate in Comparison with Other TNF Inhibitors in Patients with Rheumatoid Arthritis and High Rheumatoid Factor Titers at Baseline. a Multicentre and Retrospective Study

    Clementina López Medina1, Jerusalem Calvo2, Maria del Carmen Abalos-Aguilera3, Francisco Cepas4, Chamaida Plasencia-Rodríguez5, Ana Martinez Feito6, Alejandro Balsa5, Regina Faré-García7, Antonio Juan Mas7, Virginia Ruiz-Esquide8, Luis Sainz-Comas9, César Díaz-Torné9, Javier Godoy10, Isabel Anon Onate11, Natalia Mena Vazquez12, SARA MANRIQUE13, Marina soledad Moreno Garcia14, Rafaela Ortega Castro15 and Alejandro Escudero-Contreras16, 1Rheumatology Department, Cochin Hospital; INSERM (U1153): Clinical Epidemiology and Biostatistics, University of Paris; Rheumatology Department, Reina Sofia Hospital, Cordoba / IMIBIC / University of Cordoba, Cordoba, Spain, 2Reina Sofia University Hospital, Córdoba, Spain, 3Rheumatology Department, Reina Sofia University Hospital/Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain, 4Maimonides Institute for Biomedical Research (IMIBIC), Córdoba, Spain, 5Hospital Universitario La Paz, Madrid, Spain, 6Immuno-Rheumatology research group , Institute for Health Research (IdiPAZ), Madrid, Spain, 7Son Llazter University Hospital, Palma, Spain, 8Hospital Clinic, Rheumatology, Barcelona, Spain, 9Hospital de Santa Creu i Sant Pau, Barcelona, Spain, 10Jaen University Hospital, Jaen, Spain, 11Hospital Universitario de Jaen, Jaen, Spain, 12IBIMA, Málaga, Spain, 13Division of Rheumatology, Hospital Regional Universitario Carlos Haya, Malaga, Spain, 14Hospital Miguel Servet, Zaragoza, Spain, 15Hospital Reina Sofía, Cordoba, Spain, 16Rheumatology Department, Reina Sofia University Hospital, Cordoba/Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba, Córdoba, Spain

    Background/Purpose: Rheumatoid Factor (RF) is an antibody against the Fc fragment of IgG that contributes to the Rheumatoid Arthritis (RA) development. RF can bind the…
  • Abstract Number: 1316 • ACR Convergence 2023

    Influence of Rheumatoid Factor on Serum Drug Levels of TNF Inhibitors with Different Structures in Rheumatoid Arthritis

    Ana Martinez Feito1, Chamaida Plasencia-Rodríguez2, Marta Novella-Navarro2, Johanna E. Gehin3, Borja Hernandez-Breijo4, Claudia M.Brenis5, Alejandro Villalba6, Elisa Fernandez-Fernandez4, Irene Monjo7, Dora Pascual-Salcedo8, Pilar Nozal9 and Alejandro Balsa2, 1Immuno-Rheumatology research group , Institute for Health Research (IdiPAZ), Madrid, Spain, 2Hospital Universitario La Paz, Madrid, Spain, 3Dept. of Medical Biochemistry, Oslo University Hospital, Oslo, Norway, 4La Paz University Hospital, Madrid, Spain, 5VIB-UGent Inflammation Research Center Gent, Belgium, Gent, Belgium, 6Rheumatology Department, La Paz University Hospital, Madrid, Spain, 7University Hospital La Paz, Madrid, Spain, 8Immuno-Rheumatology Research Group, La Paz University Hospital, Madrid, Spain, 9Immunology Unit in La Paz University Hospital-Idipaz, Madrid, Spain

    Background/Purpose: Elevated rheumatoid factor (RF) in patients with rheumatoid arthritis (RA) is associated with higher disease activity. A significantly lower efficacy of TNF inhibitors (TNFi)…
  • Abstract Number: 1754 • ACR Convergence 2023

    Novel and Unique Rheumatoid Factors Cross-React with Viral Epitopes in COVID-19

    Maya Amjadi1, Maxwell Parker2, Zihao Zheng1, Alex Robbins1, Michael Denny1, Sara McCoy3, Irene Ong1 and Miriam Shelef1, 1University of Wisconsin, Madison, WI, 2University of Wisconsin-Madison, Madison, WI, 3University of Wisconsin School of Medicine and Public Health, Middleton, WI

    Background/Purpose: Rheumatoid factors (RFs), polyreactive antibodies canonically known to bind two conformational epitopes of IgG, are a hallmark of rheumatoid arthritis but also can arise…
  • Abstract Number: 1772 • ACR Convergence 2023

    Rheumatoid Arthritis-Specific Rheumatoid Factors Develop in Some COVID-19 Patients

    Adam Titi1, Ryan Adyniec2, Nat Murren1 and Miriam Shelef1, 1University of Wisconsin, Madison, WI, 2University of Wisconsin-Madison, Madison, WI

    Background/Purpose: Rheumatoid factors (RFs), antibodies canonically known to bind two conformational epitopes of IgG Fc, are a hallmark of rheumatoid arthritis (RA) but also can…
  • Abstract Number: 1915 • ACR Convergence 2023

    Scleritis and Development of Autoimmune Disease: A Case Series

    Tessalyn Morrison1, Moriah Gottman2, Marcia Friedman3 and Daniela Ghetie4, 1University of Vermont, Burlington, VT, 2Oregon Health & Science University, Milwaukie, OR, 3Alpine Immune Sciences, Inc., Beaverton, OR, 4Oregon Health & Science University, Portland, OR

    Background/Purpose: Scleritis involves inflammation of the sclera caused by trauma, infections, or autoimmune conditions. The purpose of our study was to understand the relationship between…
  • Abstract Number: 2141 • ACR Convergence 2023

    Glucocorticoid Treatment in Early Rheumatoid Arthritis Is Associated with Increased Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) Levels: A Post-hoc Analysis of a Randomized Controlled Trial (NORD-STAR)

    Kristina Lend1, Jos W.R. Twisk2, Nupur Kumar3, John Lampa4, Anna Rudin5, Merete Hetland6, Till Uhlig7, Dan Nordstrom8, Mikkel Østergaard9, Marte Schrumpf Heiberg10, Espen A Haavardsholm10, Bjorn Gudbjornsson11, Tuulikki Sokka-Isler12, Gerdur Maria Grondal13, Kim Hørslev-Petersen14, Michael Nurmohamed2, Ronald van Vollenhoven2 and Johan Frostegård3, 1Amsterdam UMC, Karolinska Institute, Stockholm, Sweden, 2Amsterdam University Medical Centers, Amsterdam, Netherlands, 3Karolinska Institutet, Stockholm, Sweden, 4Stockholm County, Hãsselby, Sweden, 5Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 6Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, 7Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, 8Helsinki University Hospital, Helsinki, Finland, 9Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark, 10Diakonhjemmet Hospital, Oslo, Norway, 11Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, 12Jyvaskyla Central Hospital, Jyväskylä, Finland, 13Department for Rheumatology, Landspitali University Hospital, Reykjavik, Iceland, 14University of Southern Denmark, Odense, Denmark

    Background/Purpose: Rheumatoid arthritis (RA) is associated with an elevated risk for developing atherosclerotic cardiovascular disease (CVD). Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key…
  • Abstract Number: 2148 • ACR Convergence 2023

    Do High RF Titers Impact Response to TNF Inhibitors? Comparison of Certolizumab Pegol and Adalimumab in Patients with RA and High Titers of RF: A Post Hoc Analysis of a Phase 4 Trial

    Josef S Smolen1, Peter C. Taylor2, Yoshiya Tanaka3, Carlos Cara4, Bernard Lauwerys5, Ricardo Xavier6, Jeffrey R Curtis7, Ted R Mikuls8 and Michael Weinblatt9, 1Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, 2Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 3University of Occupational and Environmental Health, Kitakyushu, Japan, 4UCB Pharma, Madrid, Spain, 5UCB Pharma, Brussels, Belgium, 6Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 7Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, 8Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, 9Division of Rheumatology, Inflammation and Immunity, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: In patients with RA, high RF titers are considered a poor prognostic factor and are associated with higher disease activity, risk of radiographic progression,…
  • Abstract Number: 2183 • ACR Convergence 2023

    Evolution of Lymphoma Predictors in Primary Sjogren’s Syndrome by Data Driven Analysis in Harmonized Patients

    Andreas Goules1, Loukas Chatzis2, Vasileios pezoulas3, Francesco Ferro4, Valeria Manfrè5, Dimitrios Fotiadis3, Luca Quartuccio Quartuccio6, Chiara Baldini7, Salvatore De Vita5 and Athanasios Tzioufas1, 1Dept. of Pathophysiology, School of Medicine, University of Athens, Athens, Greece, 2Dept. of Pathophysiology, School of Medicine, University of Athens, Cholargos Athens, Greece, 3Unit of Medical Technology and Intelligent Information Systems, Dept. of Materials Science and Engineering, University of Ioannina, Ioannina, Greece, 4Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, 5Clinic of Rheumatology, Dept. of Medical and Biological Sciences, Udine University, Udine, Italy, 6Rheumatology Division, Department of Medicine, University of Udine, Udine, Italy, 7University of Pisa, Pisa, Italy

    Background/Purpose: Lymphoma is the most serious complication of primary Sjogren'ssyndrome (pSS), occurring as a late sequel during disease course. So far, lymphomapredictors have been identified…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 11
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology